Novartis reveals cancer cases possibly linked to gene therapy Zolgensma

The FDA is now investigating the risk of malignancy associated with Zolgensma and is “evaluating whether regulatory action is appropriate.”

By Jonathan Gardner • Updated Nov. 9, 2026

This week in charts: 3 drug launches Wall Street is watching

The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of medicines highlighted in quarterly earnings this week.

By Ben Fidler • Nov. 6, 2026

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

Medicare will cut billions from 340B, expand site-neutral payments in 2027

Regulators finalized a rule Wednesday that would slash payments for drugs in the controversial 340B program and equalize some payments between care sites. Hospitals railed against the rule.

By Sydney Halleman • Nov. 5, 2026

Revolution’s Rasonque off to best cancer drug launch ‘in history’

Wall Street analysts are already resetting projections for Rasonque — but company executives cautioned that it’s too early to draw conclusions about the pancreatic cancer drug’s launch trajectory.

By Kristin Jensen • Nov. 5, 2026

Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts

The drug’s third-quarter sales numbers came in well above consensus estimates, widening Novo’s early edge over Eli Lilly in the latest battleground for weight loss medicines.

By Kristin Jensen • Nov. 4, 2026

CVS to split into two companies in stunning strategic about-face

The breakup, which will separate Aetna and Caremark from CVS’ retail pharmacies, is an indictment of the dogma that bigger is always better in the healthcare industry.

By Rebecca Pifer Parduhn • Nov. 4, 2026

Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.

By Jonathan Gardner • Oct. 28, 2026

Court rejects Novo bid to block Lilly obesity drug ads

Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the Danish company’s sales, a federal judge ruled.

By Jonathan Gardner • Oct. 27, 2026

[Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus

This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.

By BioPharma Dive's studioID • Oct. 6, 2026

A hidden tradeoff in Trump’s drug pricing deals

The government has announced “most-favored-nation” pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s spending on prescription drugs.

By Kelly Bilodeau • Sept. 22, 2026

Novo talks up drug launches in effort to win back investors

At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products. 

By Jonathan Gardner • Sept. 21, 2026

How J&J paved the way for Compass’ coming psychedelic drug launch

In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato.

By Jacob Bell • Sept. 21, 2026

Mid-cap biotechs join Trump’s latest round of drug pricing deals

Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.

By Jonathan Gardner • Sept. 1, 2026

Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say

Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one analyst described as a “historic” launch.

By Kristin Jensen • Aug. 27, 2026

New Jazz cancer drug approval could drive blockbuster sales

Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.

By Jonathan Gardner • Aug. 25, 2026

How cost and perception could reshape the GLP-1 market

As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.

By Kelly Bilodeau • Aug. 21, 2026

Regeneron to challenge Ipsen as FDA clears bone disease drug

Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.

By Jonathan Gardner • Aug. 20, 2026

FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax

Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.

By Alexandra Pecci • Aug. 17, 2026

Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide

Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.

By Kristin Jensen • Aug. 12, 2026

Regulatory operations: The overlooked half of submission readiness

Submission readiness extends beyond content. Early regulatory operations planning supports a compliant, high-quality application.

Aug. 10, 2026

Erica Schwartz confirmed as next CDC director

Schwartz will step into an agency that has been without a permanent leader for almost a year amid RFK Jr.’s tumultuous tenure as HHS chief. 

By Kristin Jensen • Aug. 6, 2026

Lilly climbs, Novo falls as obesity drug battle intensifies

A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.

By Kristin Jensen • Aug. 5, 2026

Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch

Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.

By Delilah Alvarado , Ben Fidler • Aug. 5, 2026

FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices

Regulators say the telehealth company illegally shared patients’ health data with advertisers and misled its customers. Hims & Hers hit back, calling the claims “baseless.”

By Jill Hughes • July 30, 2026

Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push

Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.

By BioPharma Dive staff • July 29, 2026